surrog endpoint doi bot epidemiolog medic medic term clinic trial surrog endpoint marker measur treatment correl real endpoint doe nt necessarili guarante relationship nation institut health usa defin surrog endpoint biomark intend substitut clinic endpoint surrog marker primari endpoint undesir eg death number event veri small thu impract conduct clinic trial gather statist signific number endpoint fda will accept evid clinic trial benefit surrog marker endpoint commonli exampl cholesterol elev cholesterol level increas likelihood heart diseas relationship linear mani peopl normal cholesterol develop heart diseas mani high cholesterol death heart diseas endpoint interest cholesterol surrog marker clinic trial drug exampl simvastatin zocor reduc cholesterol directli simvastatin prevent death proof zocor efficaci reduc cardiovascular diseas wa onli year origin introduct onli secondari prevent anoth case astrazeneca ha accus market rosuvastatin crestor provid hard endpoint data reli surrog endpoint compani counter test larger group patient ani drug class compar statin exampl surrog marker includ fragment blood cell surrog marker organ failur stroke ttp phase durat surrog marker breast cancer occurr count surrog marker death hiv infect critic number instanc studi surrog marker benefit treatment repeat studi endpoint ha benefit harm refer control clinic trial cohn jn introduct surrog marker circul american heart associ doi pmid pedersen tr olsson ag faergeman al lipoprotein chang reduct incid major coronari heart diseas event scandinavian simvastatin surviv studi circul psati bm weiss ns furberg cd al surrog point health outcom drug approv process treatment risk factor cardiovascular diseas jama doi pmid